$0.66
+0.00(0.58%)
Mkt Cap $847.8K
$0.61
$5.62
52-Week Range
At a Glance
AI-generated8-K
BNB Plus Corp. received a Nasdaq Notification Letter dated March 20, 2026, stating it no longer satisfies the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) based on closing bid prices for 30 consecutive business days from February 5, 2026, to March 19, 2026. The Company is ineligible for a compliance period due to prior reverse stock splits and intends to request a hearing to stay delisting, with no assurance of continued listing.$847.8K
Market Cap
$296.9K
Revenue
-$5M
Net Income
Employees46
Fundamentals
How The Business Makes Money
BNB Plus Corp. is a biotechnology company, which engages in the development and commercialization of technologies to produce and detect deoxyribonucleic acid and ribonucleic acid. It operates through the following segments: Therapeutic DNA Production Services, MDx Testing Services, and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment consists of the enzymatic manufacture of synthetic DNA for use in the production of nucleic acid-based therapeutics and the development and sale of a proprietary RNAP for use in the production of mRNA therapeutics. The MDx Testing Services segment develops clinical molecular diagnostic and genetic tests and clinical laboratory testing services. The DNA Tagging and Security Products and Services segment is involved in the detection of DNA for industrial supply chains and security services. The company was founded in 1983 and is headquartered in Stony Brook, NY.
Industry Biotechnology
Activity
What Changed Recently
Analyst View
Company Profile
CIK0000744452
ISINUS03815U6073
Phone631 240 8800
Address50 Health Sciences Drive, Stony Brook, NY, 11790, US
SEC EDGAR